Skip to main content

Table 2 Characteristics of subjects with advanced RCC with progressors versus nonprogressors on sorafenib treatment

From: Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study

Baseline characteristics* Progressors,n = 105 (80%) Nonprogressors,n = 27 (20%) P
Age, years 58 (49–64) 63 (55–73) 0.004
Age > 65 years, n (%) 17 (16) 11 (42) 0.007
Male, n (%) 76 (72) 20 (74) 1.00
Favorable prognosis**, n (%) 37 (35) 11 (40) 0.51
Radiation therapy, n (%) 22 (21) 5 (19) 1.00
High blood pressure, n (%) 35 (33) 9 (35) 1.00
Karnofsky performance status ≥90, n (%) 66 (63) 16 (59) 1.00
≥ 2 metastatic sites, n (%) 38 (36) 6 (22) 0.25
Hemoglobin, g/dL 13.9 ± 1.9 13.7 ± 1.4 0.52
Leucocytes, 109/L 6.3 (5.2–7.9) 7.1 (5.5–8.9) 0.36
Neutrophils, 109/L 3.7 (2.6–4.8) 4.2 (2.7–5.1) 0.34
Platelets, 109/L 235 (187–311) 244 (174–294) 0.70
Albumin-adj calcium, mg/dL 9.5 (9.0–9.9) 9.5 (9.2–9.8) 0.78
LDH, mg/dL 176 (150–227) 180 (162–287) 0.33
  1. * Continuous variables are expressed as mean ± SD or as median (25th–75th percentile), categorical variables are expressed as n (%). ** Favorable group was classified according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC model), in which favorable risk is equivalent to no factors. TKI Tyrosine kinase inhibitor, LDH Lactate dehydrogenase, Albumin-adj Albumin-adjusted
\